Facet arthropathy is osteoarthritis of the small paired joints at the back of each spinal segment. It matters because those joints can become a pain source on their own. Are you weighing regenerative options in 2026? The choice does not start with a shot. It starts with proof that the facet joints are the source of your pain. That is because a shot aimed at the wrong spot cannot help, no matter how it is made.
Key takeaways
- Facet arthropathy is arthritis in the small joints of the spine. Symptoms usually get worse when you lean back or twist, not when you bend forward.
- In a 2025 systematic review, the facet joints were the pain source in 15% to 41% of patients with chronic low back pain.
- Each orthobiologic shot has one target. A plan built for a disc will not address a facet joint. The reverse is just as true.
- The randomized trials comparing platelet-rich plasma with corticosteroid in facet joints are small and short-term. They are a reason to discuss PRP, not a reason to expect a fixed result.
- No orthobiologic has been shown to regrow or regenerate cartilage, and we do not describe any of them that way.
- Conservative care comes first. Surgery is considered only after conservative measures have been exhausted.
What is facet arthropathy?
The joints involved
Every spinal segment has a pair of facet joints at the back. They guide and limit motion. Like other fluid-filled joints, they have cartilage and a capsule. They can get arthritis, bone spurs, and an inflamed capsule. Cleveland Clinic’s patient education calls facet arthropathy arthritis of these small spinal joints. The cartilage wears down, and bone rubs on bone.
Who tends to develop it
Cleveland Clinic lists risk factors for facet arthropathy in adults. They include being above age 45 and having a BMI over 25. Others are disc wear, hard physical work, weak back muscles, and past spinal surgery or injury. That list is one reason we look at the whole metabolic picture. We do not treat a joint alone. Body composition and inflammation are part of the terrain the joint sits in.
Why the source matters more than the label
Doctors usually describe where pain comes from. They do not sort facet pain into types. The point is simple. The target has to match the likely source before any shot is worth a talk.
How do you know if your facet joints are causing your back pain?
How common facet-mediated pain is
A 2025 systematic review looked at treatments for enlarged facet joints. It found the facet joints were the source in 15% to 41% of patients with chronic low back pain. That is a wide range, and it carries a useful message both ways. Facet trouble is common enough that it should be looked for. It is far from universal, so it should not be assumed.
What the evaluation covers
We read your symptom pattern, exam findings, and imaging together. Then we match options to the most likely source. Imaging alone rarely settles it, because wear on a scan is common in people without pain.
Conservative care first, then reassess
We start with conservative care and track how you respond. When symptoms last, we look again at the anatomy and the goal. We do not jump straight to the most aggressive option.
What does the research say about PRP for facet joint pain?
PRP is not one product
Platelet-rich plasma is not one thing. It varies in how it is made, how strong it is, how many white cells it holds, and how much is injected. Studies compare different recipes, not one standard treatment. When you read a PRP result, you are reading a result for that protocol in that group.
The randomized comparisons that get quoted
The 2025 systematic review sums up a randomized trial of 46 people with facet-joint pain. One group got 0.5 mL of platelet-rich plasma. The other got 1.5 mL of methylprednisolone. The PRP group was reported to reach an 80.96% success rate. The same review describes a second randomized comparison in 40 people with facet-joint pain. There, PRP showed 90% effectiveness against 75% for corticosteroid.
Both are small trials, each with its own idea of success. Neither proves a lasting structural change in the joint. We use these figures to set expectations and show where the proof stops. They are not a forecast for any one patient.
Where BMAC, Lipogems, and intradiscal orthobiologics fit
Marrow- and fat-derived options
Bone marrow aspirate concentrate and Lipogems come up when the goal and the anatomy line up. We tell you plainly what is known and what is not. They sit inside a conservative-first plan, not as a shortcut past one. You can read what each option involves on our orthobiologics service page.
When the disc, not the facet, is the driver
Some cases point to a disc problem, not a facet one. Shots into the disc enter the talk only when the evaluation supports that. The point of a source-specific plan is to avoid treating the wrong structure well.
Knee language does not transfer to the spine
Patients often arrive using knee terms such as bone-on-bone. In advanced knee osteoarthritis, trial authors frame platelet-rich plasma as a safe bridge therapy prior to joint replacement. They do not frame it as something that rebuilds cartilage. Facet joints are a different anatomy with a different evidence base. So we keep the two talks separate.
Peptide and longevity medicine: a separate conversation
What these topics are and are not
Peptide and longevity medicine come up when patients want a broader, longer-horizon view of their health. At Regen.MD these are discussed as clinical and educational subjects. They are not sold, and they are not a substitute for identifying the structure generating your back pain.
Where the metabolic picture does connect
Inflammation and metabolism shape how tissue handles load and how fast it heals. That is a real part of a long-term plan. It belongs next to the procedure decision, not inside it.
Who you see
Dr. Gurpreet Singh Padda, MD, MBA, MHP
Dr. Gurpreet Singh Padda, MD, MBA, MHP directs Regen.MD and leads the Clinical Evaluation. He is a surgeon, and the practice does provide surgery when conservative measures have been exhausted. That is exactly why we take the conservative path seriously first. It is not a formality.
How decisions get made
The evaluation gives you the full picture. You learn your condition, weigh the limits of the evidence, and take part in the decision. The office is at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, next to St. Louis Lambert International Airport; details are on our St. Louis location page.
Find out whether your facet joints are the problem
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call or text us.
Frequently asked questions
What is facet arthropathy, and how is it different from disc pain?
Facet arthropathy is arthritis in the small paired joints at the back of each spinal segment. Disc pain comes from the cushion between the vertebral bodies. The two can occur together. They call for different targets. That is why the evaluation sorts them out before any shot is planned. You can review how we work through the conditions we evaluate and the pathways that follow.
Does platelet-rich plasma work for facet joint pain?
The randomized evidence is small and short-term. A 2025 systematic review sums up two randomized comparisons in people with facet-joint pain. Platelet-rich plasma did at least as well as corticosteroid. But neither trial proves a lasting structural change. Our patient education library explains how we read this kind of evidence.
Will an orthobiologic injection rebuild the cartilage in my facet joints?
No. No orthobiologic has been shown to regrow or regenerate cartilage, and we do not present any injection that way. The real goals are less pain and a joint that handles load and rehab better. That is the frame we use in our approach to care.
Are peptides part of treating facet arthropathy?
Peptides are discussed here as clinical and educational subjects. We do not sell them, and we do not present them as a treatment for a spinal joint. If your questions run toward metabolic and longevity topics, start with our physician-directed peptide therapy education. Keep it separate from the spine decision.
Who performs the evaluation?
The Clinical Evaluation is physician-led. It includes a review of your history, imaging, and metabolic data. You can read the background and training of Dr. Gurpreet Singh Padda, MD, MBA, MHP before you decide whether to request one.
What aggravates facet joint pain?
Facet arthropathy symptoms usually get worse when you lean back (extension) or twist (rotation), not when you bend forward. That pattern is a clue, not proof. The facet joints are the pain source in 15% to 41% of people with chronic low back pain. So we check your symptoms, exam, and imaging together before any treatment is aimed at them.
Is facet arthropathy the same as arthritis?
Yes. Facet arthropathy is osteoarthritis of the small paired joints at the back of each spinal segment. Like other synovial joints, they have cartilage and a capsule. They can develop cartilage wear, bone spurs, and an inflamed capsule. Arthritis on a scan is also common in people without pain. So the word on a report does not by itself prove these joints cause yours.
What is the best treatment for facet arthropathy?
The best treatment is the one aimed at the right structure. Regen.MD first confirms the facet joints are the pain source. Then we start with conservative care and track the response. If symptoms last, options such as PRP, bone marrow aspirate concentrate, or Lipogems are matched to the anatomy and the goal. Surgery is considered only after conservative measures have been exhausted.
Sources
- Hawkins N, García A, López-Candelas F, et al. Overview of Available Treatments and Their Limitations for Hypertrophic Facet Joints — A Systematic Review of the Literature. Journal of the American Academy of Orthopaedic Surgeons: Global Research and Reviews, 2025;9(1):e24.00140. https://pmc.ncbi.nlm.nih.gov/articles/PMC11703435/ — referenced for the 15% to 41% facet-source range in patients with chronic low back pain, the 46-participant PRP versus methylprednisolone comparison and its 80.96% success rate, and the 40-participant comparison reporting 90% effectiveness for PRP against 75% for corticosteroid.
- Cleveland Clinic. Facet Arthropathy. Patient education article, accessed August 2026. https://my.clevelandclinic.org/health/diseases/facet-arthropathy — referenced for the definition of facet arthropathy and the adult risk factors of age above 45 and BMI over 25.